UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016894
Receipt number R000019470
Scientific Title Multicenter prospective cohort study to identify high-risk group for primary gastric cancer using DNA methylation levels in normal-appearing gastric tissues in healthy people after Helicobacter pylori eradication
Date of disclosure of the study information 2015/03/24
Last modified on 2024/04/02 18:20:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter prospective cohort study to identify high-risk group for primary gastric cancer using DNA methylation levels in normal-appearing gastric tissues in healthy people after Helicobacter pylori eradication

Acronym

Risk prediction of gastric cancer after H. pylori eradication

Scientific Title

Multicenter prospective cohort study to identify high-risk group for primary gastric cancer using DNA methylation levels in normal-appearing gastric tissues in healthy people after Helicobacter pylori eradication

Scientific Title:Acronym

Risk prediction of gastric cancer after H. pylori eradication

Region

Japan


Condition

Condition

Gastric cancer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To demonstrate that assessment of DNA methylation levels in gastric mucosae can identify high-risk group for primary gastric cancer and enable risk stratification of healthy people after H. pylori eradication.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

disease-free survival

Key secondary outcomes

- Incidence of primary gastric cancer and metachronous gastric cancer
- Accuracy of prediction by DNA methylation markers (positive predictive value, negative predictive value, etc)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Age of 20 to 75 years old at the time of enrollment.
2) ECOG PS of 0 or 1.
3) Past infection with H.pylori confirmed by urea breath test, rapid urease test, serum H.pylori IgG Ab, microscopic analysis of a gastric biopsy specimen, cultivation, a urine antibody test, or stool antigen test.
4) Eradicated for H. pylori in or after February 2013.
5) Chronic gastritis with an open-type atrophic change at the time of eradication.
6) Successful eradication of H.pylori confirmed by urea breath test or stool antigen test.
7) Written informed consent.

Key exclusion criteria

1) Synchronous or metachronous (within 5 years) malignancies, except for carcinoma in situ or mucosal tumors curatively treated with local therapy.
2) Past history of gastrectomy, endoscopic treatment of a gastric tumor, and reconstructive surgery with a stomach tube for an esophageal cancer.
3) Past history of receiving chemotherapy (including endocrinotherapy) or radiation therapy against any other malignancies.
4) Suspicious gastric tumor by endoscopy or gastric biopsy at the time of eradication.
5) Psychosis.
6) Systemic steroid medication.
7) Individuals with two or more kinds of antiplatelet medications, with anticoagulant medication, or with coagulopathy.
8) Active gastrointestinal bleeding.
9) Individuals considered unsuitable for biopsy by an endoscopist.
10) Individuals with hereditary gastrointestinal tumors, including familial adenomatous polyposis (FAP), Lynch syndrome or Hereditary non-polyposis colorectal cancer (HNPCC), Peutz-Jeghers syndrome, Cowden syndrome, and Hereditary diffuse gastric cancer.

Target sample size

2000


Research contact person

Name of lead principal investigator

1st name Toshikazu
Middle name
Last name Ushijima

Organization

Hoshi University

Division name

President

Zip code

142-8501

Address

2-4-41 Ebara Shinagawa-ku Tokyo, Japan

TEL

+81-3-5498-5746

Email

tushijima142@hoshi.ac.jp


Public contact

Name of contact person

1st name Seiichiro
Middle name
Last name Abe

Organization

National Cancer Center Hospital, Tokyo, Japan

Division name

Endoscopy Division

Zip code

104-0045

Address

5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan

TEL

+81-3-3542-2511

Homepage URL


Email

seabe@ncc.go.jp


Sponsor or person

Institute

Hoshi University

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board, Hoshi University

Address

2-4-41 Ebara Shinagawa-ku Tokyo, Japan

Tel

03-3786-1011

Email

y-hashiguchi@hoshi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

星薬科大学(東京都)、国立がん研究センター中央病院(東京都)、湘南鎌倉総合病院(神奈川県)、日本橋大三クリニック(東京都)、長崎県壱岐病院(長崎県)、さっぽろ白石内科消化器クリニック(北海道)、和歌山県立医科大学附属病院(和歌山県)、和歌山ろうさい病院(和歌山県)、橋本市民病院(和歌山県)、有田市立病院(和歌山県)、国保日高総合病院(和歌山県)、新宮市立医療センター(和歌山県)、済生会有田病院(和歌山県)、済生会和歌山病院(和歌山県)、向陽病院(和歌山県)、中谷病院(和歌山県)、上山病院(和歌山県)、名手病院(和歌山県)、北出病院(和歌山県)、NSメディカル・ヘルスケアサービス(和歌山県)、なかた消化器・内科クリニック(和歌山県)、上田消化器・内科クリニック(和歌山県)、国保野上厚生病院(和歌山県)、中江病院(和歌山県)、富山大学附属病院(富山県)、富山県済生会富山病院(富山県)、高岡市民病院(富山県)、厚生連高岡病院(富山県)、上越総合病院(新潟県)、東京大学医学部附属病院(東京都)、東芝病院(東京都)、亀田総合病院(千葉県)、日本医科大学付属病院(東京都)、虎の門病院(東京都)、一志胃腸科クリニック(東京都)、大分大学医学部附属病院(大分県)、有田胃腸病院(大分県)、大分県厚生連鶴見病院(大分県)、あべ胃腸内視鏡クリニック(大分県)、浜松医科大学医学部附属病院(静岡県)、浜松医療センター(静岡県)、JA静岡厚生連遠州病院(静岡県)、磐田市立総合病院(静岡県)、広島大学病院(広島県)、国立病院機構呉医療センター(広島県)、国立病院機構広島西医療センター(広島県)、県立広島病院(広島県)、県立安芸津病院(広島県)、広島市立安佐市民病院(広島県)、市立三次中央病院(広島県)、広島記念病院(広島県)、呉共済病院(広島県)、済生会広島病院(広島県)、中国労災病院(広島県)、広島赤十字・原爆病院(広島県)、庄原赤十字病院(広島県)、広島総合病院(広島県)、尾道総合病院(広島県)、吉田総合病院(広島県)、JR広島病院(広島県)、三菱三原病院(広島県)、マツダ病院(広島県)、呉市医師会病院(広島県)、安芸太田病院(広島県)、本郷中央病院(広島県)、河村内科消化器クリニック(広島県)、益田内科胃腸科医院(広島県)、滋賀医科大学附属病院(滋賀県)、JCHO滋賀病院(滋賀県)


Other administrative information

Date of disclosure of the study information

2015 Year 03 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

1880

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2015 Year 03 Month 10 Day

Date of IRB

2015 Year 03 Month 24 Day

Anticipated trial start date

2015 Year 06 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Healthy people who received H. pylori eradication in or after Feb. 2013 are enrolled. Biopsy samples are taken by endoscopy from 2 fixed points in the antrum and gastric body (the lesser curvature) for DNA methylation analysis at least 10 months after successful H. pylori eradication therapy. Methylation levels of preselected genes are measured by quantitative methylation-specific PCR. Blinded to methylation information, people are followed up annually by endoscopy for 5 years to detect primary gastric cancers. An association between DNA methylation levels and the incidence of primary gastric cancer is analyzed.


Management information

Registered date

2015 Year 03 Month 24 Day

Last modified on

2024 Year 04 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019470


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name